Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Financings Of The Fortnight: Bluebird IPO Could Provide Validation For Gene Therapy As A Modality

This article was originally published in The Pink Sheet Daily

Executive Summary

During a year in which biotech IPOs have taken off, the bluebird bio issue calls for special attention. Plus news on recent financings by Quintiles, Portola, Isis and Lumena.

You may also be interested in...



Deal-Making, Financing Coalesce Around Promising CAR-T Space In Cancer

A huge IPO for Kite Pharma and two massive venture rounds for Juno Therapeutics have those two newer companies out in front in CAR therapeutics, but bigger, more established firms like Novartis, Pfizer and Celgene are in the game, while other companies, like biotech Bellicum, are looking to get in. Can Kite and Juno stay ahead and stand alone?

Cellular And Gene Therapy Trial Design: Draft Guidance Highlights Risks

FDA provides advice on designing early-phase trials to assess safety, tolerability and feasibility of administering cellular therapy and gene therapy products but stresses the unique risks of these products.

Curative Regenerative Drugs Need NICE Rethink, Key U.K. Committee Says

Health systems and health technology assessment bodies are unprepared for potentially curative gene and cell therapies, leaving drug makers and researchers in the dark, says influential U.K. parliamentary group.

Related Content

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS075696

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel